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The 5-year survival rate for pancreatic ductal adeno-
carcinoma (PDAC) remains dismal despite current 
chemotherapeutic agents and inhibitors of molecular 
targets. As the incidence of PDAC constantly increases, 
more effective multidrug approaches must be made. 
Here, we report a novel method of delivering antitu-
morigenic therapy in PDAC by upregulating the tran-
scriptional factor CCAAT/enhancer-binding protein-α 
(C/EBPα), recognized for its antiproliferative effects. 
Small activating RNA (saRNA) duplexes designed to 
increase C/EBPα expression were linked onto PDAC-
specific 2′-Fluropyrimidine RNA aptamers (2′F-RNA) 
- P19 and P1 for construction of a cell type–specific 
delivery vehicle. Both P19- and P1-C/EBPα-saRNA 
conjugates increased expression of C/EBPα and sig-
nificantly suppressed cell proliferation. Tail vein injec-
tion of the saRNA/aptamer conjugates in PANC-1 and 
in gemcitabine-resistant AsPC-1 mouse-xenografts 
led to reduced tumor size with no observed toxicity. 
To exploit the specificity of the P19/P1 aptamers for 
PDAC cells, we also assessed if conjugation with Cy3 
would allow it to be used as a diagnostic tool on archi-
val human pancreatic duodenectomy tissue sections. 
Scoring pattern from 72 patients suggested a positive 
correlation between high fluorescent signal in the high 
mortality patient groups. We propose a novel aptamer-
based strategy for delivery of targeted molecular ther-
apy in advanced PDAC where current modalities fail.
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publication 12 April 2016. doi:10.1038/mt.2016.60
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most 
common cause of cancer death in the United States, accounting 
for 30,000 deaths annually.1 Despite great efforts to improve treat-
ment for patients with pancreatic cancer, limited progress has 
been made.2,3 The majority of patients present with either local or 
systemic recurrence within 2 years following resection and post-
operative adjuvant chemotherapy.4–6 Despite numerous new drugs 
entering phase 3 trials, gemcitabine, as a single agent administered 
postoperatively, remains the current standard of care. However, 
gemcitabine only improves the 1-year survival rate from 16% to 
19%. Combinations of gemcitabine with other chemotherapeu-
tic drugs or biological agents for unresectable pancreatic cancer, 
or adjuvant treatment following resection, have resulted in lim-
ited improvement; the 5-year survival of patients with pancreatic 
cancer remains less than 5%.4–10 This limitation of conventional 
treatment is most likely due to the fast development of chemore-
sistance displayed by PDAC cells.11,12 Therefore, there remains a 
strong need for improved systemic therapies for pancreatic cancer.
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
has been recognized as an important therapeutic target in PDAC. 
However, despite the crucial role of KRAS and its mutated forms 
in PDAC, the clinical outcome of KRAS-directed therapies has not 
been successful, and KRAS is now assumed to be an undruggable 
target.13 This suggests that there are other mechanisms underlying 
PDAC progression that are independent of KRAS mutations. The 
recent correlation between oncogenic KRAS-induced senescence, 
mediated by the tumor suppressor lysine-specific demethylase 6B 
(KDM6B) in PDAC, and inhibition of tumor cell sphere forma-
tion by forced expression of CCAAT/enhancer-binding protein-α 
(C/EBPα), suggests that C/EBPα plays an important role in 
PDAC.14 In this study, we upregulate C/EBPα expression using 
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a small activating RNA (saRNA) linked with aptamer molecules 
that were directed toward a PDAC-specific epitope.
RNA activation (RNAa or saRNA) is recognized as a novel 
strategy for nonintegrative gene activation in mammalian cells by 
short 21-mer nucleotide duplexes.15,16 Targeted increase in tran-
scription is known to occur through an Argonaute-2-mediated 
mechanism and recognition of key promoter regions by the saR-
NAs to the target genes.15,16 SaRNAs targeting C/EBPα in vivo has 
previously shown to induce a potent antitumor effect in hepato-
cellular carcinoma through positive regulation of C/EBPα and its 
downstream targets including cyclin-dependent kinase inhibitor 
1  (p21). Increased levels of these targets significantly reduced 
tumor growth, and now, more evidence of antitumor effects 
through activation of p21 and E-cadherin has been observed in 
breast and lung carcinoma.17,18 This demonstrates that strategic 
choice of gene activation particularly by saRNAs can be exploited 
to assist in conventional antitumor therapy. Since reduced expres-
sion of C/EBPα is recognized in pancreatic intraepithelial neo-
plasms14; 2′-Fluropyrimidine RNA (2′F-RNA) PDAC-specific 
aptamer molecules were used as a novel vehicle to deliver C/EBPα 
saRNA into PDAC cells for activation of C/EBPα expression. 
These small, structured, single-stranded RNA aptamers are pow-
erful tools for targeting cell surface motifs and show great promise 
for clinical therapy. The tertiary structure of these nucleotide-
based molecules allows for specific epitope recognition and cell 
internalization, making them the chemical equivalent of antibod-
ies to deliver a therapeutic “payload” into target cells.
Cancer cell-specific aptamers were identified using the 
Systematic Evolution of Ligands by EXponential enrichment 
(SELEX) selection strategy.19,20 Aptamers can be selected to rec-
ognize a wide variety of targets, from small molecules to pro-
teins and nucleic acids, and have been used in cultured cells 
and ex vivo organ cultures.21–26 RNA aptamers hold their three-
dimensional structures by means of well-defined set of com-
plementary nucleic acid sequences which allows the chain to 
fold back into its natural conformation following denaturation. 
Therefore, aptamers are able to maintain their structural con-
formation even when exposed to physiologically harsh reducing 
conditions.27 As a potential molecular vehicle for therapeu-
tic delivery, RNA aptamers offer significant advantages over 
Figure 1 Naive whole cell-based SELEX. Schematic live-cell SELEX procedures. The DNA library contained 40 nt of random sequences was synthe-
sized and amplified by PCR. 2′F modified RNA aptamer library was synthesized throughout in vitro transcription. To identify the enriched RNA aptam-
ers that bind to target cells, the RNA aptamer library pool was incubated on the negative cells. After removal of nonspecific binding to the negative 
cells, the supernatant was incubated on the positive cells for positive selection. Total RNA was extracted and amplified through polymerase chain 
reaction (PCR) and in vitro transcription (IVT). The RNA aptamer selection was repeated for 14 rounds of SELEX. The enriched pools were cloned, and 
the positive clones were sequenced to identify individual RNA aptamers.
DefinedDefined Random (40 nt)
PCR
IVT
RNA aptamer library
14 Rounds
Negative cells (Huh7)
Wash
Positive cells (PANC-1)
RNA extraction
PCR
IVT
Table 1 The alignment and identification of RNA aptamers
Name Sequences Frequency (%)
P19 GGGAGACAAGAAUAAACGCUCAAUGGCGAAUGCCC GCCUAAUAGGGCGUUAUGACUUGUUGAGUUCGACAGGA 
GGCUCACAACAGGC
13(6/47)
P1 GGGAGACAAGAAUAAACGCUCAAUGCGCUGAAUGCCCAGCC GUGAAAGCGUCGAUUUCCAUCCUUCGACAGGA 
GGCUCACAACAGGC
13(6/47)
After 14 rounds of selection, the sequences of 47 clones were identified, and the frequencies of two aptamer clones are shown.
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antibodies as they show better structural stability, lower toxic-
ity, and lower immunogenicity.27
In this study, we employed a 2′F-RNA combinatorial library 
and isolated 2′F RNA aptamers (P19 and P1) through a whole 
cell-based SELEX for PDAC-targeted delivery. We linked both 
P19 and P1 aptamers to C/EBPα-saRNAs as a novel strategy 
to re-activate its epigenetically silenced target in PDAC. The 
antitumor effects of P19 or P1-C/EBPα-saRNA were assessed 
in vitro and in vivo using human pancreatic adenocarcinoma 
(PANC-1) and gemcitabine resistant AsPC-1 cell xenograft 
mouse models. Our findings demonstrate an efficient uptake 
of the saRNA-linked aptamers within PANC-1 cells compara-
ble to lipid-mediated transient transfection methods. A strong 
antiproliferative effect, possibly through mediation of p21 was 
seen in the cell lines. The xenograft models when treated with 
the aptamer-saRNA constructs also demonstrated a significant 
reduction in tumor burden. Biodistribution studies also showed 
effective localization of the P19/P1 aptamer to the tumor nod-
ule following intravenous delivery. This study heralds a novel 
approach for site-directed targeting of gene activation using 
nucleotide-based molecules with strong affinity to cancer- 
specific cell surface epitopes.
RESULTS
SELEX-screened aptamers identify cancer-specific cell 
surface epitopes
The human pancreatic adenocarcinoma, PANC-1, cells were used 
as target cells for the aptamer selection. To remove background/
irrelevant binding and select pancreatic cancer–specific aptam-
ers, the hepatocellular carcinoma cell line (Huh7) was used for 
the counter-selection step. A library of 2′F RNAs was used to 
increase nuclease resistance and enhance aptamer folding. To iso-
late 2′F RNA aptamers binding to intact cells, a library contain-
ing a 40-nt-long random sequence flanked by defined sequences 
was screened by SELEX (Figure 1). After 14 cycles of selection, a 
highly enriched aptamer pool was then cloned. Detailed selection 
conditions are summarized in Supplementary Table S1.
For comparison of individual sequences and structures, two 
different groups of aptamers were selected (Table 1). P19 and P1 
showed multistem loops and structural similarity, including a 
common motif: GAAUGCCC.
A minimum energy structural analysis of the selected aptam-
ers was carried out using NUPACK software. As depicted, 
(Figure  2a), the calculated secondary structures of the RNA 
aptamers P19 and P1 contained several stem-loop regions.
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RNA aptamers P19 and P1 show efficient cell 
internalization
Flow cytometry analyses of the individual enriched aptamer clones, 
compared to the initial RNA library, confirmed enriched cell surface 
binding to the PANC-1 cells (Figure 2b). No binding was observed 
on PANC-1 and Huh7 cells treated with Cy3-aptamers from the ini-
tial RNA library (Supplementary Figure S1). To verify the specific-
ity of the enriched aptamers to pancreatic cancer cells, a panel of five 
different pancreatic cancer cell lines AsPC-1, MIA PaCa, Capan-1 
(Figure 2c, left panel) and CFPAC-1 and BxPC3 (Supplementary 
Figure S2) were treated with Cy3-labelled P19 and P1 aptamers. 
Nonpancreatic cancer lines including Huh7, HepG2, MCF7, and 
PC3 (Figure 2c, right panel) did not show internalization of the 
Cy3-labeled aptamers. To determine whether P19 or P1 were ubiq-
uitously internalized irrespective of the status of the pancreatic cells, 
we incubated primary pancreatic epithelial cells dissociated from 
normal human pancreatic tissue with the Cy3-labeled aptamers. No 
Cy3 staining was detected in these noncancerous cells (Figure 2d). 
No staining was observed when normal T cells and B cells were 
incubated with the Cy3-labeled aptamers (Figure 2e). The binding 
affinities of P19 and P1 aptamers were quantified to 13.07 and 12.69 
nmol/l, respectively (Figure 2f,g).
C/EBPα-conjugated P19 and P1 demonstrate strong 
anti-proliferation in cultured cells
Since downregulation of C/EBPα has been previously reported to 
result in the formation of pancreatic intraepithelial neoplasms,14 we 
designed a conjugated P19 and P1 aptamer with C/EBPα-saRNA 
to exploit targeted delivery of the saRNA into pancreatic cancer 
cells for activation of C/EBPα. In order to maintain functional 
integrity of the molecule we placed “sticky sequences” (a sequence 
of 16 nucleotides that prevent structural hindrance) between 
the P19/P1 aptamer and either C/EBPα or a scrambled saRNA 
oligonucleotide (Supplementary Table S2). The P19 and P1 
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Figure 2 Aptamer secondary structure and cancer cell–specific internalization. (a) The secondary structures of P19 and P1, selected from ran-
domized N40 RNA libraries, were predicted using the Mfold software. (b) Cy3-labeled P19 and P1 aptamers were assessed for binding efficiency by 
flow cytometry in PANC-1 and control Huh7 cells. The data show the measurements of positively stained cells and representative of triplicates. (c) The 
pancreatic cell lines PANC-1, AsPC-1, MIA PaCa, and Capan-1 were treated with 100 nmol/l of the Cy3-labeled P19 and P1 aptamer and analyzed by 
confocal microscopy. All of the pancreatic lines showed punctate regions of Cy3 labeling. Nonpancreatic lines including Huh7, HepG2, MCF7, and 
PC3 cells were also treated with 100 nmol/l of Cy3-labeled P19 and P1 aptamers. No Cy3 signal was observed. Blue: Hoechst 33342. Bar = 10 µm. 
(d) Normal primary pancreatic cells were treated with 100 nmol/l Cy3-labeled aptamers and imaged by confocal microscopy. Blue: Hoechst 33342. 
Bar = 10 µm. (e) Flow cytometry analysis of normal T and B cells treated with Cy3-labeled P19 and P1 aptamers. (f and g) The dissociation constant 
(KD) was measured by flow cytometry using increasing concentrations of Cy3-labeled aptamers (from 15.6 to 500 nmol/l). Mean fluorescence inten-
sity was measured and calculated using a one-site binding model for nonlinear regression.
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conjugates showed successful PANC-1 internalization (Figure 3a). 
To investigate gene activation in vitro, the P19 and P1 conjugated 
C/EBPα-saRNA or scrambled RNAs were added to PANC-1 cell 
culture media in the absence of any transfection reagent. Cells 
treated with the conjugated C/EBPα-saRNA aptamers showed 
significantly higher levels of C/EBPα mRNA (Figure  3b) and 
its downstream target, p21 (Figure 3c) when compared to a 
scrambled-saRNA. The P19-C/EBPα-saRNA construct induced 
a 5-fold increase in C/EBPα transcript (P = 0.029) and a 50-fold 
increase in p21 transcript level ((P = 0.03), two-tailed t-test with 
Welch’s correction at 95% confidence interval; Table 2). P1-C/
EBPα-saRNA construct induced a 1.3-fold increase in C/EBPα 
transcript (P = 0.01) and a 1.4-fold increase in p21 transcript 
level ((P = 0.026), two-tailed t-test with Welch’s correction at 95% 
confidence interval; Table 2). Since C/EBPα is known to stabilize 
the cyclin-dependent kinase inhibitor (p21) to elevate expression 
levels and block cyclin-dependent kinases for cell cycle arrest,28 
we performed a WST-1 cell proliferation assay on PANC-1 cells 
Figure 3 Internalization and biological effects of conjugated aptamers in PANC-1 cells. (a) Cy3-labeled P19- or P1-conjugated C/EBPα-saRNAs 
were incubated with PANC-1 cells. Red: Cy3-labeled RNA, Blue: Hoechst 33342. (b) Relative transcript expression (qPCR) for C/EBPα mRNA and 
(c) p21 mRNA was quantified by real-time PCR. CEBPA expression increased fivefold (P = 0.029) and p21 increase 57.6-fold (P = 0.033) by P19-
CEBPα-saRNA conjugated aptamer or 1.29-fold (P = 0.015) and 1.4-fold (P = 0.026), respectively, by P1- CEBPα-saRNA-conjugated aptamer. (t-test 
with Welch’s correction at 95% confidence interval). (d) A WST-1 cell proliferation assay was performed in PANC-1 cells. At 96 hours, only 22.9% of 
total cells were proliferating following treatment with P19-CEBPα-saRNA and 28% of total cells proliferation following P1-C/EBPα-saRNA. Both P19-
Scramble-saRNA and P1-Scramble-saRNA demonstrated cytostatic effects on the cells. (e) Western blot analysis was carried out in PANC-1 cells treated 
with P19- or P1-conjugated C/EBPα–saRNA or scrambled saRNA aptamers. Membranes were probed with anti-C/EBPα and anti-actin (control). Band 
intensity from three representative blots was analyzed (right panel). P19 and P1- C/EBPα -saRNA treatment induced a threefold increase in CEBPA 
signal relative to untreated cells. P19 and P1-scramble conjugate treatment both induced a twofold increase in CEBPA signal.
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treated with the conjugated aptamers for 96 hours. We observed 
more than 80% reduction in cell proliferation following treatment 
with either P19- C/EBPα-saRNA (Figure 3d, left panel) or P1-C/
EBPα-saRNA (Figure 3d, right panel); (P = 0.011, paired t-test at 
5% confidence interval; Table 3).
A western blot analysis of CEBPA protein extracted from the 
treated PANC-1 cells demonstrated three times higher band inten-
sity in cells treated with P19-C/EBPα-saRNA when compared to 
P1-C/EBPα-saRNA (Figure 3e and Table 4). We also observed at 
least a twofold increase in CEBPA signal from cells treated with 
scramble conjugated aptamer (Figure 3e and Table 4). Since the 
P19/P1 aptamer target is linked with the c-Myc/CEBPA signal-
ing network,29 the aptamers may be modulating a functional effect 
within this network which may not be picked up at the transcript 
level, but clearly observable at the protein level and from the WST 
assay where P19/P1–scramble conjugate showed a cytostatic 
response (Figure 3d). We are currently investigating the signaling 
network induced by the aptamer target.
Injection of C/EBPα-conjugated P19 and P1 in 
luciferase reporter xenografts leads to a reduction in 
tumor growth
To investigate the antitumor effects of C/EBPα-saRNA in vivo, 
100 and 250 pmol of P19-C/EBPα-saRNA and P1-C/EBPα-
saRNA conjugates were delivered systemically into human pan-
creatic cancer xenografts via tail vein injection. A significant 
reduction in tumor growth (Figure 4a) and bioluminescent signal 
(Figure 4b,c) was observed in the treated groups, when compared 
to scramble control-treated and untreated animals. This observa-
tion confirmed the known antiproliferative effects of C/EBPα in 
PDAC. We then compared the antitumor effects of C/EBPα to 
gemcitabine over a period of 4 weeks. P19-C/EBPα-saRNA dem-
onstrated 30% more efficient antitumor response when compared 
to gemcitabine by 4 weeks (Figure 4d). When the same study 
Table 4 Table summary of band intensity from western blot on PANC1 
cells treated with P19/P1 scramble and CEBPA
P19-CEBPA P1-CEBPA
Untreated
P19- 
Scr
P19-
CEBPA Untreated
P1- 
Scr
P1- 
CEBPA
Number of 
values
3 3 3 3 3 3
Minimum 3.46 6.12 8.57 1.30 2.05 3.3
Median 3.49 6.44 9.25 1.84 2.22 3.38
Maximum 3.57 6.92 10.88 2.20 2.37 4.93
Mean 3.51 6.50 9.56 1.78 2.21 3.87
SD 0.056 0.40 1.19 0.45 0.16 0.92
SE 0.03 0.23 0.68 0.26 0.09 0.53
Lower 95% 
CI of mean
3.37 5.50 6.62 0.65 1.83 1.59
Upper 95% 
CI of mean
3.64 7.49 12.51 2.90 2.60 6.14
Sum 10.52 19.48 28.69 5.34 6.64 11.6
Table 3 Table summary of percentage cell proliferation in PANC1 cells 
treated with P19/P1 scramble and CEBPA at 96 hours
Untreated P19-Scr P19-CEBPA P1-Scr P1-CEBPA
Number of values 3 3 3 3 3
25% percentile 118.4 50.53 16.99 72.8 19.59
Median 165.2 51.65 21.71 75.88 21.52
75% percentile 172.4 120 30.13 140.3 43.04
Mean 152 74.07 22.94 96.34 28.05
SD 29.34 39.82 6.66 38.13 13.02
SE 16.94 22.99 3.84 22.01 7.516
Lower 95% CI of 
mean
79.1 −24.84 6.41 1.62 −4.29
Upper 95% CI of 
mean
224.9 173 39.48 191.1 60.39
Sum 455.9 222.2 68.83 289 84.15
Table 2 Statistical analysis of CEBPA and p21 transcript levels
Table analyzed
CEBPA mRNA p21 mRNA
CEBPA (P1) CEBPA (P19) CEBPA (P1) CEBPA (P19)
Column B versus column C P1-Scr versus P1-CEBPA P19-Scr versus P19-CEBPA P1-Scr versus P1-CEBPA P19-Scr versus P19-CEBPA
Unpaired t-test with Welch’s correction
P value 0.015 0.0297 0.0262 0.0333
P value summary * * * *
Are means significantly different? (P < 0.05) Yes Yes Yes Yes
One- or two-tailed P value? Two-tailed Two-tailed Two-tailed Two-tailed
Welch-corrected t, df t = 5.043, df = 3 t = 5.671, df = 2 t = 4.101, df = 3 t = 5.343, df = 2
How big is the difference?
Mean ± SEM of column B 0.9794 ± 0.03213, N = 3 0.7549 ± 0.09829, N = 3 0.9170 ± 0.1015, N = 3 1.050 ± 0.2052, N = 3
Mean ± SEM of column C 1.296 ± 0.05385, N = 3 5.617 ± 0.8516, N = 3 1.422 ± 0.07790, N = 3 57.62 ± 10.58, N = 3
Difference between means −0.3162 ± 0.06270 −4.862 ± 0.8573 −0.5246 ± 0.1279 −56.57 ± 10.58
95% confidence interval 0.5157 to −0.1167 −8.550 to −1.173 −0.9316 to −0.1176 −102.1 to −11.03
R2 0.8945 0.9415 0.8486 0.9346
*P < 0.05
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was performed in xenografts using gemcitabine-resistant human 
pancreatic adenocarcinoma cells, the only significant antitumor 
effect was observed in the P19-C/EBPα-saRNA-treated group. 
Gemcitabine showed no response (Figure 4e) and with no evi-
dence of blood toxicity in response to P19-C/EBPα-saRNA as 
indicated by analysis of hemoglobin, white blood cells, neutrophil, 
and platelet counts (Figure 4f).
Cy3-conjugated RNA aptamers P19 and P1 may be 
exploited as a tool for immunohistochemistry on 
pancreatic biopsies
Frozen tissue sections from 72 patients with pancreatic can-
cer were used to determine the staining efficiency of Cy3-P19 
and Cy3-P1 aptamers. As staining controls, lung, fat tissue, 
muscle, kidney (Supplementary Figure S3, left panel), liver, 
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bone marrow, brain, and spleen biopsies (Supplementary 
Figure S3, right panel) were also screened. Pancreatic tumor 
sites and adjacent nontumor sections were subjected to stan-
dard antigen retrieval for conventional immunohistochemistry 
(Supplementary Figure  S4). P19 staining appeared cytoplas-
mic on pancreatic cancer region specifically (Supplementary 
Figure S4, inset) with a correlation coefficient score of 0.891 
between P19 and P1 (Figure 5). Scoring criteria was therefore 
established for the staining intensity of the 72 patient samples 
to include low- (<7), medium- (>7 and <14), and high-level 
staining (>14 and <20) (Table 5). The mean survival period was 
21.0 ± 2.6 months for the low-level P1 staining group, 15.9 ± 3.2 
months for the medium-level P1 staining group, and 13.1 ± 4.4 
months for the high-level P1 staining group. The mean sur-
vival period was 21.0 ± 2.6 months for the low-level P19 stain-
ing group, 15.6 ± 3.3 months for the medium-level P19 staining 
group, and 13.1 ± 4.3 months for the high-level P19 staining 
group (Table 2). The staining intensity between each survival 
group showed statistically significant differences (mean ± SD 
relative to low staining group).
Figure 4 In vivo effects of P19 and P1- C/EBPα-saRNA. (a) P19- and P1-conjugated C/EBPα-saRNA aptamers were injected in PANC-1 engrafted 
mice via tail vein injection at 100 and 250 pmol. Tumor size was calculated by the formula 0.52 × length × width × width. Data are presented as 
the mean ± SD (n = 4 each group) (b) Tumor growth was monitored by evaluating bioluminescence before the first injection and 1 week after the 
last injection. The photons (left) and bioluminescent signal changes (right) were quantified. (c) Bioluminescent images of the xenografts are a rep-
resentative of each treatment groups. (d) Comparison of the antitumor effect of C/EBPα-saRNA with gemcitabine. P19-conjugated C/EBPα-saRNA 
aptamers were injected in PANC-1 engrafted mice by tail vein injection at 1 nmol. Gemcitabine were injected by i.p. at 3 mg on day 5 and 7 for 4 
weeks. Data are presented as the mean ± SD (n = 6 each group) (e) The antitumor effects in gemcitabine-resistant AsPC-1 cells in vivo were assessed. 
P19-conjugated C/EBPα-saRNA aptamers were injected in AsPC-1-engrafted mice by tail vein injection at 1 nmol. Data are presented as the mean ± 
SD (PBS: n = 6, P19-CEBP: n = 5, P19-Scr: n = 3, gemcitabine: n = 3). Tumor growth was monitored by evaluating bioluminescence before the first 
injection and 1 week after the last injection. The percentage of the cells that had metastasized to the ascites was measured. (f) To assess cytotoxicity 
following gemcitabine treatment, the blood parameter for hemoglobin, white blood cell count, platelets, and neutrophils were measured. Data are 
presented as the mean ± SD (n = 6 each group).
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samples from patients with pancreatic adenocarcinoma were stained 
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DISCUSSION
Advanced PDAC still remains a fatal disease, and in most cases, 
dysfunctional KRAS signaling appears to be the most common 
cause. Despite recognition of this target, many attempts to abro-
gate its response have failed. New and more effective treatments 
for advanced PDAC must therefore be found. RNA aptamers are 
becoming attractive therapeutic molecules due to their safety 
and effectiveness. Their high specificity, low toxicity and low 
immunogenicity led to the first FDA approval in 2004, for an 
aptamer-based treatment for neovascular age-related macular 
degeneration.30 To date, aptamers have been widely investigated 
for biomarker discovery, in vitro diagnosis, in vivo imaging, and 
targeted therapy. There have been few other reports of aptamer-
based therapies that target pancreatic cancer; for instance, Kim 
et al.31 recently reported the development of a pancreatic adeno-
carcinoma-specific aptamer that targets the growth factor PAUF 
(pancreatic adenocarcinoma up regulated factor). In this study, we 
selected two RNA aptamers (P19 and P1) that specifically recog-
nize pancreatic cancer cells, with the aim of using them as delivery 
vehicles for saRNA treatment.
Since C/EBPα is a known transcription factor that suppresses 
tumor growth in PDAC and is epigenetically silenced in aggressive 
forms of this disease, it was recognized as an appropriate factor 
to target for this study.14,28,32 By linking a duplex C/EBPα-saRNA 
molecule to pancreatic cancer-specific P19 and P1 aptamers, we 
demonstrated efficient endocytic uptake in pancreatic cells and a 
significant increase in C/EBPα transcript and protein levels. This 
chemical-free induction of expression was similar to the results 
achieved using lipid transfection of C/EBPα-saRNA, as previously 
reported.17 The aptamers conjugated with scrambled nonspecific 
RNA also showed a slight increase in CEBPA protein expression 
which was not observed at the transcript level. This therefore sug-
gests that the aptamers alone might also be modulating a functional 
posttranslational effect within the CEBPA network to regulate cell 
cycle progression as observed from the WST-1 cell proliferation 
assay. The identity of the aptamer epitope and its functional role in 
PANC-1 cells is currently under further characterization.
Confocal images of fluorescently labeled (Cy3)-P19 and P1 
aptamers showed punctate staining within the cytoplasm of pan-
creatic cancer cell lines, with no uptake observed in normal pri-
mary pancreatic cells or in human breast and prostate cancer cell 
lines. This suggests that P19 and P1 displays a cancer-specific epi-
tope recognition motif and efficient uptake within cells bypassing 
the need for toxic and complex synthetic carrier molecules.
This report is the first to provide evidence of an antitumor 
response in a gemcitabine-resistant pancreatic tumor-xenograft 
animal model. P19-C/EBPα-saRNA induced a 40% decrease in 
tumor growth with no evidence of toxicity to the host. Although 
this rate of decrease may not as yet prove useful for treating human 
cancer, it is the first study to demonstrate a targeted approach of 
treating pancreatic cancer. Since the specificity and delivery of 
aptamers can be improved significantly by simply modifying the 
components of the nucleic acid chain, this study paves the way 
for increasing the efficiency of this type of vehicle to significantly 
reduce side effects associated with current adjuvant antitumor 
therapies and even potentially be used as a diagnostic marker to 
stratify patients to specific survival groups.
MATERIALS AND METHODS
Cell lines. The following cell lines were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA) for use as targets for SELEX, 
PANC-1 (CRL-1469), Capan-1 (HTB-79), CFPAC-1 (CRL-1918), MIA 
PaCa-2 (CRL-1420), BxPC-3 (CRL-1687), and AsPC-1 (CRL-1682). 
Primary human pancreatic epithelial cells (ACBRI 515) were purchased 
from Cell Systems (Kirkland, WA). Huh-7 cells were purchased from 
Japanase Collection of Research Bioresources. The cells were cultured 
according to the cell bank’s instructions.
Whole-cell SELEX. The SELEX cycle was performed basically as described by 
Tuerk and Gold.20 In vitro selection was carried out essentially as described,33 
with a few modifications for this study. The DNA library contained 40 nt of 
random sequences was synthesized by Integrated DNA Technologies (IDT, 
Coralville, IA). The random region was flanked by constant regions for the 
amplification. The DNA random library was amplified by PCR and con-
verted to RNA library using the DuraScribe kit (Epicentre, Madison, WI). 
In the transcription reaction mixture, CTP and UTP were replaced with 2′F-
CTP and 2′F-UTP to allow ribonuclease-resistant RNA. For the first round, 
6 nmols of the RNA library was incubated with target cells (PANC-1) in 1 ml 
binding buffer (phosphate-buffered saline solution (PBS) without Ca2+ and 
Mg2+, 5 mmol/l MgCl2, 0.01% BSA, yeast tRNA (100 µg/ml)). The human 
pancreatic adenocarcinoma, PANC-1, cells were used as target cells for the 
aptamer selection. To remove irrelevant binding, the hepatocellular carci-
noma cell line, Huh7, was used for the counter-selection step. RNAs that 
bound to target cells were recovered, amplified by RT-PCR and in vitro tran-
scription, and used in the following selection rounds. In subsequent rounds, 
the RNA concentration was reduced by 10–folds, and the incubation time 
was reduced to create more stringent conditions. To avoid nonspecific bind-
ing to the cell surface, yeast tRNA (Sigma, St. Louis, MO) was used competi-
tors. After 14 rounds of SELEX, each clone of aptamers were TA cloned.
Live-cell confocal imaging. For the aptamer internalization studies, 1 × 105 
cells were seeded in 35 mm glass-bottom dishes (MatTek, Ashland, MA) 
and grown in medium for 24 hours. The RNAs were labeled with Cy3 using 
the Cy3 Silencer siRNA labeling kit (Ambion, Austin, TX). Cy3-labeled 
RNAs were added to the cells at 100 nmol/l and incubated for 1 hour. The 
images were taken using a Zeiss LSM 510 Meta Inverted 2 photon confo-
cal microscope system (Oberkochen, Germany) using a C-Apo 40x/1.2NA 
water immersion objective.
Flow cytometry-based binding assays. Aptamer binding and uptake was 
also assessed by flow cytometry. For the assay, the PANC-1 cells were 
Table 5 Scoring criteria for P19 and P1 immunohistochemistry
P19 P1
Low (<7) Medium (>7 and <14) High (>14 and <20) Low (<7) Medium (>7 and <14) High (>14 and <20)
Number of patients 3 26 43 3 26 43
Survival period 21.0 ± 2.64 15.6 ± 3.30* 13.0 ± 4.29** 21.0 ± 2.64 15.9 ± 3.17* 13.1 ± 4.36**
Scoring criteria were established for the staining intensity of the 72 patient samples: low, medium, and high. Mean ± SD. *P < 0.05; **P < 0.005 when compared to 
low staining group.
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detached using a nonenzymatic cell dissociation solution, washed with 
PBS, and suspended in binding buffer. Next, Cy3-labeled aptamers were 
added and incubated with PANC-1 cells for 30 minutes at 37 °C. Cells were 
washed with binding buffer and immediately analyzed by Fortessa flow 
cytometry (BD, San Jose, CA). For the exclusion of dead cells, 4′6′-diamid-
ino-2-phenylindole (DAPI) (1 µg/ml; Vector Laboratories, Burlingame, 
CA) was used. Each flow-cytometry assay was performed in triplicate. The 
data were analyzed with FlowJo software.
To determine the apparent dissociation constant (KD) of aptamers 
to PANC-1 cells, the mean fluorescence intensity was calculated for each 
concentration and for the unselected library controls. The values for 
the controls were considered to be background fluorescence and were 
subtracted from the values for the aptamers, as previously described by 
Sefah et al.34 The dissociation constants were calculated using a one-site 
binding model. The nonlinear curve regression was performed using 
Graph Pad Prism (GraphPad Software, La Jolla, CA).
Immunofluorescence staining for Cy3-P1 and Cy3-P19. Pancreatic 
cancer tissue samples were obtained from patients at National Taiwan 
University Hospital. The slides were deparaffinized two times in xylene 
for 15 minutes each and rinsed with 100% ethanol, followed by 95, 80, 
and 70% ethanol and then distilled water. For antigen retrieval, tissue sec-
tions were heated in a microwave oven at 120 °C for 10 min in 10 mmol/l 
sodium citrate buffer (pH 6.0). After two washes with PBS, the sections 
were quenched by incubating them for 10 minutes in 0.3% H2O2. The sec-
tions were then incubated with blocking serum (10% serum) for 1 hour 
at room temperature. The sections were then incubated in a 1/100 dilu-
tion of the primary antibodies, Cy3-P1 and Cy3-P19, at 4 °C overnight. 
The primary antibodies were directly labeled with Cy3. After incubation 
at 4 °C, the slides were washed three times with PBS and then mounted in 
a mounting solution containing the nuclear stain 4′6′-diamidino-2-phe-
nylindole (DAPI). The stained sections were viewed under a Zeiss Axio 
Vert. A1 fluorescent microscope at ×100 magnification. The slides were 
scored using five independent fields per slide, and the activity in each field 
was evaluated by the following scoring system: score of 0, no fluorescent 
signal; score of 1, 1–25% of the cells contain a fluorescent signal; score of 
2, 26–50% of the cells contain a fluorescent signal; score of 3, 51–75% of 
the cells contain a fluorescent signal; score of 4, more than 76% of the cells 
contain a fluorescent signal.
WST-1 assay. The WST-1 measurement was performed according to the 
manufacturer’s standard protocol (Takara Bio Europe). Briefly, cells were 
cultured into 96-well plate at a density of 2.5 × 105 cells per well as three 
independent replicates. Ten microliters of the WST-1 reagent was added 
and incubated for a duration of 1 hour with spectrophotometry readings at 
420 and 620 nm taken every 15 minutes.
Aptamer conjugate to saRNA using “sticky sequences” (STICK). 
P1-STICK, P19-STICK, Sense-STICK, and antisense RNAs were chemi-
cally synthesized by the Synthetic and Biopolymer Chemistry Core in the 
City of Hope. The P1-STICK and P19-STICK RNAs were refolded in bind-
ing buffer, heated to 95 °C for 3 minutes, and then slowly cooled to 37 °C. 
The incubation was continued at 37 °C for 10 minutes. The sense-STICK 
and antisense strand were annealed to the complementary partners using 
the same molar amounts as the corresponding partner strand to form 
the STICK-C/EBPα RNAs or scrambled RNAs. The same amount of the 
refolded P1- and P19-STICK was added and incubated at 37 °C for 10 min-
utes in binding buffer to form the P1- and P19- STICK-C/EBPα RNAs or 
the P1- and P19- STICK-scrambled RNAs.
Relative gene expression analysis by qPCR and protein expression by 
western blot analysis. For analyzing gene activation and protein expression, 
PANC-1 cells were seeded into 24-well plates at a density of 1 × 105 cells per 
well. P19 and P1, conjugated with C/EBPα-saRNAs or scrambled saRNAs, 
were added directly to the cells, in duplicate, at a final concentration of 80 
nmol/l, for RNA and protein extraction. The treatment was repeated 24 
hours later, and the cells were harvested at the 72-hour time point. The total 
RNA was extracted for reverse transcription (QuantiFast Reverse transcrip-
tion, Qiagen, Hilden, Germany) and target cDNA amplification by real-
time PCR (QuantiFast SYBRGreen Master mix, Qiagen). The cDNA probes 
used were: C/EBPα (NM_007678) and the reference gene gluceraldehyde-
3-phosphate-dehydrogenase GAPDH (NM_008084, XM_001003314, 
XM_990238) using QuantiTect SYBR Probes from Qiagen. The total pro-
tein was extracted using a conventional RIPA buffer (50 mmol/l Tris–HCl, 
150 mmol/l sodium chloride, 1.0% Igepal, 0.5% sodium deoxycholate, and 
0.1% sodium dodecyl sulfate). The total protein content was then quan-
titated using a Bradford assay, following the manufacturer’s instructions 
(Bio-Rad, Hercules, CA). The total protein extracts were separated by SDS–
PAGE and transferred onto PVDF membranes, then were probed with 
antibodies against C/EBPα (Sigma, 1:500, SAB4500111, St. Louis, MO) or 
actin (Abcam, 1:5,000, ab8226, Cambridge, UK). The proteins of interest 
were detected with an HRP-conjugated secondary antibody (1:5,000) and 
visualized with LI-COR (Lincoln, Nebraska) Western Sure ECL substrate, 
according to the manufacturer’s protocol.
In vivo assays of antitumor effects. To establish the traceable tumor ani-
mal models, subcutaneous implantations were performed by injecting 25 
μl of a monocellular suspension containing 106 PANC-1 or AsPC-1 cells 
expressing luciferase and a 25 μl growth factor-reduced matrigel matrix 
(BD Biosciences, San Jose, CA) under the dorsal skin of 6-week-old female 
nonobese diabetic/severe combined immunodeficiency (NOD/SCID) 
mice (BioLasco, Taiwan).
The firefly luciferase fragment was inserted into a pcDNA-3.1(+) 
backbone, which also encodes ampicillin resistance for selection in 
bacteria and the neomycin resistance gene for selection in mammalian 
cells. The recombinant constructs were purified using the QIAGEN 
plasmid midi kit. PANC-1 and AsPC-1 cells were transfected with the 
recombinant constructs for 24 hours. The following day, the culture 
medium was replaced with standard medium containing 1.2 mg/ml G418 
(Merck, Germany) for stable clone selection. Two weeks after selection, a 
single stable cell line was picked and maintained in medium containing 
1.2 mg/ml G418. Luciferase expression was assessed using the Luciferase 
Assay System. Tumors developed to about 1 × 1 cm in approximately 
3 weeks after inoculation.
Each subgroup of mice was injected with 100 pmol, 250 pmol, or 
1 nmol aptamer-STICK-saRNA via tail vein 4 times/week for 3 weeks and 
sacrificed 1 week after the last injection. Tumor growth was monitored by 
evaluating bioluminescence using an IVIS 200 live animal imaging system. 
The tumors were evaluated before the first injection and 1 week after the 
last injection. Prior to the in vivo imaging, the mice were anesthetized 
using isoflurane. A solution of 150 μg/kg d-luciferin (Biosynth, Staad, 
Switzerland) was then injected by the intraperitoneal route. The mice were 
imaged and bioluminescent signals were analyzed using the Living Image 
Software (Caliper Life Sciences, Alameda, CA). Tumor size was measured 
with a ruler and calculated by the formula 0.52 × length × width × width.
Statistical analysis. Statistically significant differences were determined by 
Students t-test and Mann–Whitney test using Graph Pad Prism software 
(GraphPad Software, La Jolla, CA).
SUPPLEMENTARY MATERIAL
Figure S1. Internalization assay of initial RNA aptamer library (prior 
to enrichment) in PANC-1 and Huh7.
Figure S2. Internalization of P19 in various pancreatic cancer cell 
lines.
Figure S3. Negative staining of Cy3-P19 and P1 in non pancreatic 
lines
Figure S4. Cy3-P19 signal from frozen human tissue section.
Table S1. Summary of cell-SELEX.
Table S2. Sequence information of P19, P1, sense and antisense 
CEBPAsaRNA strands.
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